LENZ Therapeutics Inc.
LENZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$127.61M
Close$
$1.05
74.2% downside
Current Fair Value
74.2% downsideOvervalued by 74.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $127.61 Million |
|---|---|
| Enterprise Value | $104.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.85 |
| Beta | 1.63 |
| Outstanding Shares | 31,374,311 |
Return
| Return on Equity | -57.47% |
|---|---|
| Return on Assets | -53.26% |
| Return on Invested Capital | -60.86% |
Valuation & Multiples
| P/E Ratio | -1 |
|---|---|
| PEG | -0.87 |
| Price to Sales | - |
| Price to Book Ratio | 0.68 |
| Enterprise Value to Revenue | 4.86 |
| Enterprise Value to EBIT | -0.78 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
$2.38 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$4.49 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3573▼ 95.56% |
|---|---|
| Total Calls | 147,500▲ 41.55% |
| Total Puts | 200,200▼ 16.93% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 111.21%▲ 4.56% |
|---|---|
| Total Invested | $198.27M▼ 34.63% |
| Investors Holding | 1520% |
ESG Score
No data
About LENZ Therapeutics Inc.
119 employeesgraphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of...